Grace Therapeutics, Inc. Common Stock

Day range

$1.67 – $1.99

Open

$1.94

Prev close

$1.93

Volume

440.35K

Market cap

$40.6M

Shares out

21.04M

P/E

—

P/S

—

P/B

0.84

P/FCF

—

ROE

-41.9%

ROA

-40.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsSep 18, 2026

  On September 17, 2026, Grace Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Meeting"). Set forth below are the matters acted upon by the Company's stockholders at the Meeting and the final voting results on each matter.

• Private placementAug 6, 2026

  On August 4, 2026, Grace Therapeutics, Inc. (the "Company"), in connection with a private placement offering (the "Offering") of the Company's common stock, par value $0.0001 (the "Common Stock"), entered into with certain institutional and accredited investors (the "Investors") (i) a securities purchase agreement (the "Purchase Agreement"), and (ii) a registration rights agreement (the "Registration Rights Agreement"). Pursuant to the Purchase Agreement, the Company offered and sold in the Offering an aggregate of 4,761,904 shares of Common Stock (the "Shares") at a purchase price of $2.10 per share.

• Investor presentationJul 28, 2026

  the Company updated its corporate presentation on July 28, 2026 to reflect the path to NDA resubmission following the Type A Meeting

• Investor presentationJun 18, 2026

  On June 18, 2026, Grace Therapeutics, Inc. updated its corporate presentation. A copy of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated by reference into this Item 8.01.

• Executive officer departureJun 5, 2026

  Carrie D'Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026, which was approved by the Company on June 1, 2026.

Days to cover

19.0

Short interest

1.72M

Avg volume

90.44K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
  negativeGlobeNewswire Inc.· Jun 3, 2026
• Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
  positiveGlobeNewswire Inc.· Apr 14, 2026
• Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
  positiveGlobeNewswire Inc.· Feb 25, 2026
• Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
  positiveGlobeNewswire Inc.· Feb 10, 2025